Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Peter Gann, University of Illinois at Chicago
First received: November 14, 2011
Last updated: April 17, 2014
Last verified: April 2014
The overall goal of this project is to quantify the long-term effects of dutasteride on the architectural and nuclear features of benign prostate tissue, using state-of-the art digital image analysis techniques. The ultimate result will be a multivariable morphological "signature" that could provide a useful indicator of an individual's degree of drug response.
||Observational Model: Case Control
Time Perspective: Cross-Sectional
||Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue
Primary Outcome Measures:
- Architectural Features [ Time Frame: Year 4 ] [ Designated as safety issue: No ]
To characterize and quantify the effects of dutasteride on histological (architectural) features of benign prostate tissue via comparison of a random sample of Year 4 biopsy specimens from the dutasteride and placebo groups.
- Morphometric features [ Time Frame: Year 4 ] [ Designated as safety issue: No ]
To quantify the long-term (Year 4) effects of dutasteride on nuclear morphometric features (i.e., size, shape and texture) in benign prostatic epithelial cells.
To develop and validate a multivariable morphological score based on summarization of differences between drug- and placebo-treated tissues.
- Independent changes in architecture and morphometry [ Time Frame: Year 4 ] [ Designated as safety issue: No ]
To determine the degree to which drug-related changes at Year 4 in architectural and nuclear features are independent of (i.e., not explained by) changes in serum DHT, gland volume and PSA.
Secondary Outcome Measures:
- Changes in cytomorphology [ Time Frame: Year 2 & Year 4 ] [ Designated as safety issue: No ]
To determine, by comparing Year 2 to Year 4 samples within individuals, whether drug-related cytomorphological changes are constant, declining or progressing.
Biopsy tissue (Year 2 and Year 4) already collected in REDUCE trial
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2015 (Final data collection date for primary outcome measure)
No PCa at Year 2 or Year 4
No PCa at Year 2 or Year 4
|Ages Eligible for Study:
||50 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Cross-sectional comparison of biomarkers in prostate biopsy tissue (Year 2 and Year 4) already collected in REDUCE trial
- completed REDUCE trial (Year 4 exit biopsy with blocks and HE slides available; i.e., U.S. participants only)
- compliant with assigned treatment based on either: (dutasteride group) at least 3 post-baseline serum DHT levels ≥ 50% lower than baseline, or (placebo group) at least 3 post-baseline serum DHT levels with none showing ≥ 50% decrease from baseline
- subgroup: Year 2 biopsy blocks and HE slides available for Aim 4a
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01473030
|University of Illinois at Chicago
|Chicago, Illinois, United States, 60612 |
University of Illinois at Chicago
||Peter H Gann, MD, ScD
||University of Illinois at Chicago
No publications provided
||Peter Gann, Professor and Director, Division of Pathology Research, University of Illinois at Chicago
History of Changes
|Other Study ID Numbers:
|Study First Received:
||November 14, 2011
||April 17, 2014
||United States: Institutional Review Board
Keywords provided by University of Illinois at Chicago:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 01, 2015
5-alpha Reductase Inhibitors
Molecular Mechanisms of Pharmacological Action